Document is current
Any future updates will be listed below
-
Authors
Catlett, Ian M. https://orcid.org/0000-0001-6220-2626
Gao, Lu https://orcid.org/0000-0002-2206-5476
Hu, Yanhua https://orcid.org/0000-0002-8149-5636
Banerjee, Subhashis https://orcid.org/0009-0000-1365-5207
Krueger, James G. https://orcid.org/0000-0002-3775-1778
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb
- License Information
-
More Information
Article History
Received: 28 May 2024
Accepted: 20 August 2024
First Online: 16 September 2024
Declarations
:
: Ian M. Catlett was an employee of and shareholder in Bristol Myers Squibb at the time of study conduct. Lu Gao and Yanhua Hu are employees of and shareholders in Bristol Myers Squibb. Subhashis Banerjee was an employee of and shareholder in Bristol Myers Squibb at the time of study conduct. James G. Krueger has received research grants from Bristol Myers Squibb during the conduct of the study, personal fees from AbbVie, Baxter, Biogen, Delenex, Kineta, Sanofi, Serono, and Xenoport, and research grants from Amgen, Dermira, Innovaderm, Janssen, Kadmon, Kyowa, Lilly, Merck, Novartis, Paraxel, and Pfizer outside the submitted work.
: This biomarker study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki. The protocol, amendments, and patient informed consent received appropriate approval by the institutional review board or independent ethics committee prior to the initiation of the trial at the study center. All patients provided written informed consent before any study-related procedures were performed.
